Immune checkpoint inhibitors increase the risk of hypothyroidism in patients with primary head and neck cancer compared to other cancers

被引：0
|
作者：
Alaber, Omar [1 ]
Chandar, Apoorva [1 ]
Mendiratta, Prateek [1 ]
Patel, Monaliben [1 ]
Hoimes, Chris [1 ]
Lavertu, Pierre [1 ]
Mangla, Ankit [1 ]
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P710
引用
收藏
页数：2
相关论文
共 50 条
  • [31] In Patients Treated With Immune Checkpoint Inhibitors, Myocarditis is Infrequent Compared With Other Cardiovascular Events
    Hsia, Judith A.
    Thurston, Jessica
    Kondapalli, Lavanya
    Miller, Ronni
    Dale, Rita
    Bonaca, Marc P.
    CIRCULATION, 2020, 142
  • [32] Second primary cancers in head and neck cancer patients: a challenging entity
    de Castro, Gilberto, Jr.
    Awada, Ahmad
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 203 - 204
  • [33] Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis
    Tang, Lingrong
    Liu, Tingting
    Chen, Jun
    Dang, Jun
    Li, Guang
    IMMUNOTHERAPY, 2021, 13 (06) : 541 - 555
  • [34] Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors
    Pan, Cassie
    Wu, Qian Vicky
    Voutsinas, Jenna
    Houlton, Jeffrey J. J.
    Barber, Brittany
    Rizvi, Zain H. H.
    Marchiano, Emily
    Futran, Neal
    Laramore, George E. E.
    Liao, Jay J. J.
    Parvathaneni, Upendra
    Martins, Renato G. G.
    Fromm, Jonathan R. R.
    Rodriguez, Cristina P. P.
    CANCER MEDICINE, 2023, 12 (08): : 9384 - 9391
  • [35] Utilization of Immunotherapy in Head and Neck Cancers Pre-Food and Drug Administration Approval of Immune Checkpoint Inhibitors
    Wu, S. P. P.
    Tam, M.
    Gerber, N. K.
    Li, Z.
    Schmidt, B.
    Persky, M.
    Sanfilippo, N. J.
    Tran, T.
    Jacobson, A.
    DeLacure, M.
    Hu, K. S.
    Persky, M.
    Schreiber, D. P.
    Givi, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1366 - 1367
  • [36] Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker
    Oualla, Karima
    Castelo Branco, Luis
    Nouiyakh, Lamiae
    Amaadour, Lamiae
    Benbrahim, Zineb
    Arifi, Samia
    Mellas, Nawfel
    CANCER CONTROL, 2021, 28
  • [37] Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries
    Chuang, Shu-Chun
    Scelo, Ghislaine
    Tonita, Jon M.
    Tamaro, Sharon
    Jonasson, Jon G.
    Kliewer, Erich V.
    Hemminki, Kari
    Weiderpass, Elisabete
    Pukkala, Eero
    Tracey, Elizabeth
    Friis, Soren
    Pompe-Kirn, Vera
    Brewster, David H.
    Martos, Carmen
    Chia, Kee-Seng
    Boffetta, Paolo
    Brennan, Paul
    Hashibe, Mia
    INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (10) : 2390 - 2396
  • [38] Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries
    Chuang, S. C.
    Scelo, G.
    Tonita, J. M.
    Tamaro, S.
    Jonasson, J. G.
    Kliewer, E. V.
    Hemminki, K.
    Weiderpass', E.
    Pukkala, E.
    Tracey, E.
    Friis, S.
    Pompe-Kirn, V.
    Brewster, D. H.
    Martos, C.
    Chia, K. S.
    Boffetta, P.
    Brennan, P.
    Hashibe, M.
    EJC SUPPLEMENTS, 2008, 6 (09): : 194 - 194
  • [39] Head and Neck Cancer Compared With Other Cancers-Does the Great Equalizer Equalize Equally?
    Deschler, Daniel G.
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2019, 145 (03) : 249 - 250
  • [40] Adverse jaw outcomes from immune checkpoint inhibitors for head and neck cancer? Case reports
    Subramanian, Gayathri
    Yeung, Vincent
    Baredes, Soly
    Kim, Sung
    Bergsbaken, Tessa
    Quek, Samuel Y. P.
    QUINTESSENCE INTERNATIONAL, 2024, 55 (03): : 244 - 249
12345